Usefulness of [(111)In-DTPA(0)] octreotide scintigraphy in a family with von Hippel-Lindau disease(391 views) Pulcrano M, Camera L, Pagano L, Del Vecchio S, Ferone D, Bodei L, Murgia A, Pace L, Storto G, Paganelli G, Colao A, Salvatore M, Lombardi G, Biondi B
Keywords: [111in-Dtpa0], Mibg Scintigraphy, Neuroendocrine Tumors, Octreotide Scintigraphy, Pheochromocytoma, Von Hippel-Lindau Disease, (3 Iodobenzyl)guanidine I 131, 10 Tetraazacyclododecane 1, 10 Tetraacetic Acid Octreotide[3 Tyrosine] Y 90, C Peptide, Catecholamine, Gastrin, Insulin, Iopromide, Lysine, Neuron Specific Enolase, Pentetreotide In 111, Radiopharmaceutical Agent, Somatostatin Derivative, Somatostatin Receptor, 111in Octreotide, Dtpa(0), 111in-Octreotide, Diagnostic Agent, Drug Derivative, Indium, Pentetic Acid, Adrenalectomy, Adult, Angioma, Article, Blood Toxicity, Case Report, Contrast Enhancement, Diagnostic Value, Female, Follow Up, Genetic Association, Genetic Counseling, Human, Human Tissue, Hypertension, Immunohistochemistry, In Vitro Study, In Vivo Study, Liver Metastasis, Multiple Cycle Treatment, Pancreas Tumor, Pancreaticoduodenectomy, Paraganglioma, Pedigree Analysis, Protein Expression, Retina Tumor, Scintiscanning, Spiral Computer Assisted Tomography, Tachycardia, Treatment Refusal, Tumor Volume, Von Hippel Lindau Disease, Whole Body Scintiscanning, Computer Assisted Emission Tomography, Methodology, Indium Radioisotopes, Emission-Computed, (3 Iodobenzyl) Guanidine I 131, 10 Tetraacetic Acid Octreotide [3 Tyrosine] Y 90, Dtpa (0),
Affiliations: *** IBB - CNR ***
Department of Clinical and Molecular Endocrinology and Oncology, Federico II University of Naples, Via S. Pansini 5, 80131 Naples, Italy
Department of Biomorphological and Functional Sciences, Federico II University of Naples, Naples, Italy
Department of Endocrinological and Metabolic Sciences (DISEM), University of Genoa, Genoa, Italy
Department of Nuclear Medicine, European Institute of Oncology, Milan, Italy
References: Not available.
Usefulness of [(111)In-DTPA(0)] octreotide scintigraphy in a family with von Hippel-Lindau disease
The identification of patients with von Hippel-Lindau (VHL) disease dictates accurate genetic counseling of family members, whereas screening for early detection of visceral and neurological involvement is usually performed by a combination of radiological and nuclear medicine techniques such as ultrasonography or contrast-enhanced computed tomography of the upper abdomen, magnetic resonance imaging of the central nervous system and 131I-metaiodobenzylguanidine-scintigraphy. The role of 111-indium-diethylenetriaminepentaacetic acid [111In-DTPA0] octreotide scintigraphy in this clinical context has never been investigated. Here, we report imaging findings in a VHL patient and in 3 consecutive family members undergoing clinical and radiological screening that included [111In-DTPA0] octreoticle scintigraphy in addition to the above-mentioned procedures. Somatostatin receptor expression was investigated in vitro by immunohistochemistry in pancreatic tumor sections. On the basis of in vivo and in vitro findings, octreotide long-acting release treatment followed by 90Y-1, 4, 7, 10-Tetraazacyclododecane-N, N', N'', N'''-tetraacetic acid (DOTA0) -Tyr3-octreotide led to a lack of progression in this patient although this result is a possibility which needs to be proved by further investigation and longer follow-up. The results of this study suggest that [111In-DTPA0] octreotide scintigraphy may be helpful in the routine work-up of VHL patients for diagnostic and therapeutic purposes. 2008, Editrice Kurtis
Usefulness of [(111)In-DTPA(0)] octreotide scintigraphy in a family with von Hippel-Lindau disease